This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This week in the Beyond the Basics/Treatment section of our website, we’ve posted an article about another treatment under investigation called IPI-145 or duvelisib, a PI3 kinase inhibitor. You can read about how it works, the data that has been released and ongoing clinical trials here.
In other news, the FDA expanded the Imbruvica® (ibrutinib) label to include overall survival data in previously untreated CLL and added a new indication for small lymphocytic lymphoma (SLL) patients. Read more about it in our News section here.
THANK YOU AGAIN TO OUR READER POLL PARTICIPANTS! Data analysis is in progress and we are really excited with the preliminary results. We really appreciate the time you spent to contribute to our research and look forward to sharing the data in the future.
NEW – Thursday, May 19th WEBCAST at 1:00 PM EDT: Hosted by the Leukemia and Lymphoma Society, this 90 minute webcast on CLL will cover the latest information on CLL. Dr. Susan O’Brien from University of California, Irvine is the speaker and she will do a super job. Find out more information and register here.
From time to time, we will make you aware of in-person meetings coming up for those of us affected by CLL. In May and June, they include:
May 21st at 7:30 AM in Needham, MA: The Lymphoma Workshop: Understanding Lymphoma Basics and Current Treatment Options will be hosted by the Lymphoma Research Foundation. You can find out more information and register here. There is no charge to attend.
June 16th at 6 PM in Salt Lake City, UT: The Lymphoma Research Foundation will be hosting Updates on Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma as part of their Ask the Doctor series. You can find out more information and register here. There is no charge to attend.
In the meantime….
We are all in this together.
Brian Koffman, MD
Volunteer Medical Director of the CLL Society